Skip to main content
SpringerLink
Log in

Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Yeo W, Johnson PJ . Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209–220.

    Article  CAS  PubMed  Google Scholar 

  2. Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134: 1470–1481.

    Article  CAS  PubMed  Google Scholar 

  3. Watanabe T, Tanaka Y . Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol Res 2013; 43: 113–121.

    Article  PubMed  Google Scholar 

  4. Pardanani A . Ruxolitinib for myelofibrosis therapy: current context, pros and cons. Leukemia 2012; 26: 1449–1451.

    Article  CAS  PubMed  Google Scholar 

  5. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;; e-pub ahead of print 26 April 2013; doi:10.1038/leu.2013.119.

    Article  CAS  PubMed  Google Scholar 

  6. Shi H, Lu L, Zhang NP, Zhang SC, Shen XZ . Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment. World J Gastroenterol 2012; 18: 3617–3622.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Puro R, Schneider RJ . Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol 2007; 81: 7351–7362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 2012; 5: 552.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799–807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wang YH, Fan L, Wang L, Zhang R, Xu J, Fang C et al. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy. Support Care Cancer 2013; 21: 1265–1271.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Sciences, Hematology Unit, University of Cagliari, Cagliari, Italy

    G Caocci, F Murgia, S Atzeni & G La Nasa

  2. Bone Marrow Transplant Center, R. Binaghi Hospital, Cagliari, Italy

    G Caocci & G La Nasa

  3. Hematology Unit, University Hospital, Sassari, Italy

    L Podda

  4. Department of Biomedical Science, University of Sassari, Sassari, Italy

    A Solinas

Authors
  1. G Caocci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Murgia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Podda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Solinas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Atzeni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G La Nasa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Caocci.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caocci, G., Murgia, F., Podda, L. et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 28, 225–227 (2014). https://doi.org/10.1038/leu.2013.235

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.235

  • Springer Nature Limited

This article is cited by

Search

Navigation